https://www.selleckchem.com/pr....oducts/rogaratinib.h
Overall, the correlation between median PFS and median OS was weak (R = 0.20. 95% Confidence Intervals [CI]-0.02;0.42). Surrogacy robustness varied between treatment classes and PFS endpoints. In ICI trials only, the correlations between Q1-PFS and Q1-OS and between 12-month PFS-RMST and 12-month OS-RMST were high (R = 0.89, 95%CI 0.78-0.98, and 0.80, 95% CI 0.63-0.96, respectively). Interaction -values obtained by meta-regression confirmed the robustness of results. In trials of systemic therapies for advanced HCC, the surrogate re
Like
Comment
Share
